Powder: -20°C for 3 years | In solvent: -80°C for 1 year
B2 (Linazolamide intermediate B impurity 2) promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 68.00 | |
5 mg | In stock | $ 155.00 | |
10 mg | In stock | $ 247.00 | |
25 mg | In stock | $ 418.00 | |
50 mg | In stock | $ 596.00 | |
100 mg | In stock | $ 863.00 | |
500 mg | In stock | $ 1,720.00 |
Description | B2 (Linazolamide intermediate B impurity 2) promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease |
Synonyms | Linazolamide intermediate B impurity 2, CPNQ, 5-[4-(4-Chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline |
Molecular Weight | 396.83 |
Formula | C20H17ClN4O3 |
CAS No. | 115687-05-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: 2 mg/mL
DMSO: < 39.68 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
B2 115687-05-3 Chromatin/Epigenetic DNA Damage/DNA Repair Others Sirtuin Parkinson’s diseases Huntington’s diseases Linazolamide intermediate B impurity 2 B 2 Inhibitor CPNQ B-2 inhibit 5-[4-(4-Chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline inhibitor